211 related articles for article (PubMed ID: 25367997)
1. The 340B discount program: outpatient prescription dispensing patterns through contract pharmacies in 2012.
Clark BL; Hou J; Chou CH; Huang ES; Conti R
Health Aff (Millwood); 2014 Nov; 33(11):2012-7. PubMed ID: 25367997
[TBL] [Abstract][Full Text] [Related]
2. The 340B drug discount program: hospitals generate profits by expanding to reach more affluent communities.
Conti RM; Bach PB
Health Aff (Millwood); 2014 Oct; 33(10):1786-92. PubMed ID: 25288423
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive Legislative Reform to Protect the Integrity of the 340B Drug Discount Program.
Zeta LM
Food Drug Law J; 2015; 70(4):481-99, i. PubMed ID: 26827389
[TBL] [Abstract][Full Text] [Related]
4. Revenues and Profits From Medicare Patients in Hospitals Participating in the 340B Drug Discount Program, 2013-2016.
Conti RM; Nikpay SS; Buntin MB
JAMA Netw Open; 2019 Oct; 2(10):e1914141. PubMed ID: 31664442
[TBL] [Abstract][Full Text] [Related]
5. Examining the Benefits of the 340b Drug Discount Program.
Gerlach J; McSweeney S; Swearingen A; Coustasse A
Health Care Manag (Frederick); 2018; 37(3):225-231. PubMed ID: 29901471
[TBL] [Abstract][Full Text] [Related]
6. The 340b Program, Contract Pharmacies, Hospitals, and Patients: An Evolving Relationship Impacting Health Care Delivery.
Ruley M; Belcher M; Sayre H; Coustasse A
Health Care Manag (Frederick); 2019; 38(4):311-321. PubMed ID: 31663869
[TBL] [Abstract][Full Text] [Related]
7. Ensuring access to prescription medications in the post-ACA healthcare access landscape: the essential role of FQHCs in the safety net for the underinsured.
Shi L; Wharton MK; Monnette A
Am J Manag Care; 2018 Mar; 24(5 Suppl):S67-S73. PubMed ID: 29620813
[TBL] [Abstract][Full Text] [Related]
8. Challenges for Managed Care from 340B Contract Pharmacies.
Fein AJ
J Manag Care Spec Pharm; 2016 Mar; 22(3):197-203. PubMed ID: 27003548
[TBL] [Abstract][Full Text] [Related]
9. Association of 340B contract pharmacy growth with county-level characteristics.
Nikpay S; Gracia G; Geressu H; Conti R
Am J Manag Care; 2022 Mar; 28(3):133-136. PubMed ID: 35404549
[TBL] [Abstract][Full Text] [Related]
10. Estimated Changes in Manufacturer and Health Care Organization Revenue Following List Price Reductions for Hepatitis C Treatments.
Dickson S; Reynolds I
JAMA Netw Open; 2019 Jul; 2(7):e196541. PubMed ID: 31276176
[TBL] [Abstract][Full Text] [Related]
11. Using 340B drug discounts to provide a financially sustainable medication discharge service.
Wu T; Williams C; Vranek K; Mattingly TJ
Res Social Adm Pharm; 2019 Jan; 15(1):114-116. PubMed ID: 29606609
[TBL] [Abstract][Full Text] [Related]
12. Impact of the 340B Pharmacy Program on Services and Supports for Persons Served by Hemophilia Treatment Centers in the United States.
Malouin RA; Mckernan L; Forsberg A; Cheng D; Drake J; McLaughlin K; Trujillo M
Matern Child Health J; 2018 Sep; 22(9):1240-1246. PubMed ID: 29948762
[TBL] [Abstract][Full Text] [Related]
13. The unintended consequences of the 340B safety-net drug discount program.
Thomas S; Schulman K
Health Serv Res; 2020 Apr; 55(2):153-156. PubMed ID: 32114714
[No Abstract] [Full Text] [Related]
14. Notice regarding section 602 of the Veterans Health Care Act of 1992 inclusion of outpatient hospital facilities--PHS. Notice.
Fed Regist; 1994 Jun; 59(107):29300-1. PubMed ID: 10135125
[TBL] [Abstract][Full Text] [Related]
15. Specialty Drug Price Trends in the Federal 340B Drug Discount Program.
Lee CH; Chang J; McCombs J
J Manag Care Spec Pharm; 2019 Feb; 25(2):178-187. PubMed ID: 30698090
[TBL] [Abstract][Full Text] [Related]
16. Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program.
Jones EA; Linas BP; Truong V; Burgess JF; Lasser KE
PLoS One; 2019; 14(3):e0213745. PubMed ID: 30870475
[TBL] [Abstract][Full Text] [Related]
17. Value of the 340B Drug Discount Program.
Kantarjian H; Chapman R
JAMA Oncol; 2015 Nov; 1(8):1029-30. PubMed ID: 26313652
[No Abstract] [Full Text] [Related]
18. Trends in Proportion of Medicare Part D Claims Subject to 340B Discounts, 2013-2020.
Dickson S; Gabriel N; Hernandez I
JAMA Health Forum; 2023 Nov; 4(11):e234091. PubMed ID: 37976048
[TBL] [Abstract][Full Text] [Related]
19. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule.
Health Resources and Services Administration, Department of Health and Human Services (HHS)
Fed Regist; 2017 Jan; 82(3):1210-30. PubMed ID: 28071875
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of the 340B Drug Pricing Program: A Scoping Review.
Knox RP; Wang J; Feldman WB; Kesselheim AS; Sarpatwari A
JAMA Health Forum; 2023 Nov; 4(11):e233716. PubMed ID: 37991784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
